Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Ongericimab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Ongericimab is a cholesterol-lowering antibody injection for adults with high LDL ("bad") cholesterol. It was developed in China by Shanghai Junshi Biosciences and is sold there as JUNSHIDA® (君适达®). Junshi says it was the first Chinese-developed PCSK9 medicine approved for people who cannot take statins.
China's National Medical Products Administration (NMPA) first approved it in October 2024 and added two more uses in May 2025. Alongside a healthy diet, it is approved for adults with:
It is a prescription heart and cholesterol medicine and should be started and followed up by a cardiologist or lipid specialist.
The liver pulls LDL cholesterol out of the blood using LDL receptors. A protein called PCSK9 latches on to these receptors and has them destroyed. Ongericimab is a lab-made humanised antibody (IgG1 type) that binds PCSK9 and keeps it away from the receptors. More receptors stay on the liver cells to clear LDL, so blood levels drop.
All the main trials were randomised, double-blind and compared with placebo:
Non-HDL cholesterol, apolipoprotein B and total cholesterol also came down. These trials measured cholesterol levels rather than heart attacks or strokes.
Ongericimab is injected under the skin. Each pre-filled syringe or autoinjector pen holds 150 mg in 1 mL. The schedules used in the trials were:
The exact approved schedule for each use is in the Chinese prescribing information, and your cardiologist decides which one is right for you.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Side effects: Junshi reports no new safety signals in the main JS002-003 trial, and in the inherited-cholesterol trial side effects were about as common as with placebo. Detailed side-effect percentages had not been published in the sources we reviewed, so your doctor will go through the full list in the Chinese prescribing information.
Before you start: tell your cardiologist about every medicine you take, any allergy to antibody medicines, and whether you are pregnant, planning a pregnancy or breastfeeding. The sources we reviewed did not include safety data for pregnancy, breastfeeding or children.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval and is not sold in Indian pharmacies, and we found no US FDA or European approval.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. You can also see how we handle other imported heart medicines, such as Camzyos.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The pre-filled syringes or pens are stored and shipped exactly as directed on the Chinese pack, using temperature-controlled shipping to the patient or hospital. Each device holds one 150 mg dose, so we work out the number needed from the schedule your doctor prescribes. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or treating hospital on a valid doctor's prescription.
Delhi's cardiology centres treat many people with inherited or hard-to-control cholesterol, and our New Delhi base keeps delivery quick.
Doctors in Mumbai can request the pens or syringes for a named patient, with the full cost shared in writing first.
Patients in Bangalore can receive each supply at home or at the clinic managing their cholesterol.
Lipid and heart clinics in Chennai can arrange access for patients who cannot take statins or whose LDL stays high.
We match the number of devices in each shipment to the dosing schedule the doctor has set.
Shipments to Kolkata and eastern India are packed to keep within the conditions printed on the pack.
Patients in Pune use the same documented import route, with updates shared at each step.
A cardiologist in Ahmedabad can send us the prescription and lipid reports to start the process.
Patients across Rajasthan can be supplied without travelling, once the import is cleared in their name.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to home or the treating hospital.
We coordinate delivery for patients seen by cardiologists in public and private hospitals across Uttar Pradesh.
Patients in Kerala can have their supply delivered in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
